Search hospitals > Texas > Amarillo
The Don and Sybil Harrington Cancer Center
Claim this profileAmarillo, Texas 79106
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast cancer
Conducts research for Ovarian Cancer
91 reported clinical trials
4 medical researchers
Summary
The Don and Sybil Harrington Cancer Center is a medical facility located in Amarillo, Texas. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer, Ovarian Cancer and other specialties. The Don and Sybil Harrington Cancer Center is involved with conducting 91 clinical trials across 172 conditions. There are 4 research doctors associated with this hospital, such as Anita Ravipati, Brian T. Pruitt, Daniel Arsenault, and Jeffery D. Hanrahan.Area of expertise
1Lung Cancer
Global LeaderStage II
Stage III
Stage IV
2Breast Cancer
Global LeaderHER2 negative
ER positive
PR positive
Top PIs
Anita RavipatiThe Don and Sybil Harrington Cancer Center2 years of reported clinical research
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
30 reported clinical trials
56 drugs studied
Brian T. PruittThe Don and Sybil Harrington Cancer Center6 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
2 reported clinical trials
4 drugs studied
Daniel ArsenaultThe Don and Sybil Harrington Cancer Center11 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
2 reported clinical trials
6 drugs studied
Jeffery D. HanrahanThe Don and Sybil Harrington Cancer Center8 years of reported clinical research
Studies Testicular cancer
Studies Ovarian Carcinoma
1 reported clinical trial
5 drugs studied
Clinical Trials running at The Don and Sybil Harrington Cancer Center
Lung Cancer
Breast Cancer
Cancer
Pancreatic Cancer
Non-Small Cell Lung Cancer
Testicular cancer
Bladder Cancer
Breast cancer
Colorectal Cancer
Prostate Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Tepotinib + Ramucirumab
for Lung Cancer
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.
Recruiting1 award Phase 24 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at The Don and Sybil Harrington Cancer Center?
The Don and Sybil Harrington Cancer Center is a medical facility located in Amarillo, Texas. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer, Ovarian Cancer and other specialties. The Don and Sybil Harrington Cancer Center is involved with conducting 91 clinical trials across 172 conditions. There are 4 research doctors associated with this hospital, such as Anita Ravipati, Brian T. Pruitt, Daniel Arsenault, and Jeffery D. Hanrahan.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.